Signaturefd LLC Purchases 8,544 Shares of Johnson & Johnson (NYSE:JNJ)

Signaturefd LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 17.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,063 shares of the company's stock after buying an additional 8,544 shares during the period. Signaturefd LLC's holdings in Johnson & Johnson were worth $9,629,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. Hudson Value Partners LLC increased its position in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares in the last quarter. Proficio Capital Partners LLC raised its holdings in shares of Johnson & Johnson by 22.0% in the fourth quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company's stock worth $2,885,000 after acquiring an additional 3,594 shares during the last quarter. IMG Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $483,000. Finally, Creative Financial Designs Inc. ADV raised its holdings in shares of Johnson & Johnson by 7.6% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 9,509 shares of the company's stock worth $1,375,000 after acquiring an additional 668 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.9%

NYSE JNJ traded down $1.44 on Tuesday, reaching $155.38. The company had a trading volume of 6,860,493 shares, compared to its average volume of 8,081,536. The stock's 50 day moving average is $153.79 and its 200-day moving average is $154.63. The stock has a market cap of $373.86 billion, a price-to-earnings ratio of 17.28, a PEG ratio of 2.14 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on JNJ shares. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Raymond James Financial decreased their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Morgan Stanley reaffirmed an "underperform" rating on shares of Johnson & Johnson in a research report on Thursday, July 10th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $171.00.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.